0KBU Stock Overview
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Omeros Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.99 |
| 52 Week High | US$7.78 |
| 52 Week Low | US$0.99 |
| Beta | 1.33 |
| 1 Month Change | -15.80% |
| 3 Month Change | -19.87% |
| 1 Year Change | -50.00% |
| 3 Year Change | -84.07% |
| 5 Year Change | -82.99% |
| Change since IPO | -82.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KBU | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -7.9% | 8.3% | 2.2% |
| 1Y | -50.0% | 4.9% | 0.9% |
Return vs Industry: 0KBU underperformed the UK Pharmaceuticals industry which returned 0.2% over the past year.
Return vs Market: 0KBU underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| 0KBU volatility | |
|---|---|
| 0KBU Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0KBU's share price has been volatile over the past 3 months.
Volatility Over Time: 0KBU's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 198 | Greg Demopulos | www.omeros.com |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders.
Omeros Corporation Fundamentals Summary
| 0KBU fundamental statistics | |
|---|---|
| Market cap | US$176.15m |
| Earnings (TTM) | -US$174.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs 0KBU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KBU income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$69.78m |
| Gross Profit | -US$69.78m |
| Other Expenses | US$105.14m |
| Earnings | -US$174.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -1,354.0% |
How did 0KBU perform over the long term?
See historical performance and comparison